KR20190114400A - Method for producing fermentation products of sanghwang mushroom - Google Patents
Method for producing fermentation products of sanghwang mushroom Download PDFInfo
- Publication number
- KR20190114400A KR20190114400A KR1020180037046A KR20180037046A KR20190114400A KR 20190114400 A KR20190114400 A KR 20190114400A KR 1020180037046 A KR1020180037046 A KR 1020180037046A KR 20180037046 A KR20180037046 A KR 20180037046A KR 20190114400 A KR20190114400 A KR 20190114400A
- Authority
- KR
- South Korea
- Prior art keywords
- situation mushroom
- mushroom
- present
- culture
- fermented
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 235000001674 Agaricus brunnescens Nutrition 0.000 title claims description 87
- 238000000855 fermentation Methods 0.000 title claims description 28
- 230000004151 fermentation Effects 0.000 title claims description 28
- 229920002498 Beta-glucan Polymers 0.000 claims abstract description 33
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims abstract description 32
- 239000001963 growth medium Substances 0.000 claims abstract description 7
- 238000009630 liquid culture Methods 0.000 claims abstract description 5
- 239000000284 extract Substances 0.000 claims description 35
- 238000000034 method Methods 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 241000675108 Citrus tangerina Species 0.000 claims 1
- 241000001727 Tropicoporus linteus Species 0.000 abstract description 9
- 238000011218 seed culture Methods 0.000 abstract description 3
- 239000008681 Phellinus linteus extract Substances 0.000 abstract 4
- 201000011510 cancer Diseases 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 5
- 235000013376 functional food Nutrition 0.000 description 5
- 210000002865 immune cell Anatomy 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000001965 potato dextrose agar Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- -1 maltose and sucrose Chemical compound 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 244000305267 Quercus macrolepis Species 0.000 description 2
- 235000016976 Quercus macrolepis Nutrition 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001605 Alcohol poisoning Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000221198 Basidiomycota Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 240000001462 Pleurotus ostreatus Species 0.000 description 1
- 235000001603 Pleurotus ostreatus Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 241000789545 Trimeria grandifolia Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/065—Microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/208—Fungi extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/502—Gums
- A23V2250/5034—Beta-Glucan
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법에 관한 것으로, 보다 상세하게는, 발효된 상황버섯 배양물로부터 상황버섯 발효 추출물을 추출함으로써, 베타글루칸의 함량을 대폭 증가시킨 상황버섯 발효 추출물의 제조 방법에 관한 것이다.The present invention relates to a method for producing a fermented extract of beta glucan containing a high content of beta glucan, and more particularly, by extracting the fermented mushroom fermentation extract from the fermented mushroom mushroom culture, the situation mushroom significantly increased the content of beta glucan It relates to a method for preparing a fermented extract.
버섯은 자루와 갓이 있는 균사체를 지칭하는 것으로, 보통 담자균과 대형 자낭균을 말한다. 이러한 버섯 중 식용 가능한 지의류를 말하기도 하는 버섯은, 예를 들어 가장 흔한 표고버섯, 송이버섯, 느타리버섯, 팽이버섯, 양송이버섯을 포함하여 다양한 종류가 있으며 그 효능 또한 다양하고, 특히 약용 효과가 우수한 버섯으로 상황버섯(Phellinus linteus)이 공지되어 있는데, 이러한 상황버섯은 고산지대에 서식하고 있는 산뽕나무, 참나무, 밤나무, 상수리나무 등의 고목에서 자생하는 번식이 잘되지 않는 매우 희귀한 다년생 버섯으로 담자균문, 균심강, 민주름버섯목, 소나무비늘버섯과, 진흙버섯속에 속하며, 진한 황색을 띄고 있다 하여 상황버섯으로 불린다. Mushrooms refer to mycelium with sacks and lampshade, usually called basidiomycetes and large streptococci. Among these mushrooms, edible lichens are edible, for example, the most common shiitake mushrooms, matsutake mushrooms, oyster mushrooms, enoki mushrooms, mushrooms, mushrooms, and various kinds of efficacy, especially medicinal effect is excellent Phellinus linteus is known as a mushroom, which is a very rare perennial mushroom that does not grow well in the old trees such as wild mulberry, oak, chestnut and oak trees in the alpine region. It belongs to the genus Moon, Kyunsimgang, Democratic Mushroom, Pine Scaly Mushroom, and Mud Mushroom.
상기한 특징을 갖는, 상황버섯은 예로부터 귀중하게 사용되어 온 한약재로서 중풍, 임질, 해독, 이뇨, 건위, 이질, 부인과, 지한제 등의 치료제로 이용되어 왔으며, 근자에는 매우 강력한 항암작용을 하는 것으로 확인되어 인공재배에 관한 연구가 많이 이루어지고 있다. 상황버섯의 자실체(fruit body)는 초기에는 진흙덩어리가 뭉쳐진 것 같은 형태로 유지되다가 겨울이 되면 성장을 멈추고 노란부분이 진흙색으로 변하며 다시 봄이 되면 노랗게 덧 자라는 다년생 버섯으로, 다 자란 후의 모습은 나무 그루터기에 혓바닥을 내민 모습이어서 수설 이라고도 한다. 혓바닥 같은 형태의 윗부분은 진흙과 같은 색깔을 나타내기도 하고 감나무의 표피와 같이 검게 갈라진 모습 등으로 나타나기도 하며, 아랫부분은 노란 융단 같은 형태로, 윗부분은 검은색 또는 진흙색으로 나타나기도 한다. 그리고 달이면 노랗거나 담황색으로 맑게 나타나며, 맛이 순하고 담백하여 먹기에 좋고 향이 없는 게 특징이다.Situation mushrooms, which have the above characteristics, have been used as medicines for treatment of stroke, gonorrhea, detoxification, diuresis, health, dysentery, gynecology, antiperspirant, etc., which have been used preciously since ancient times. There is a lot of research on artificial cultivation. The fruit body of the situation mushroom is a perennial mushroom that is maintained in the form of agglomeration of mud at first, but stops growing in winter, turns yellow to mud, and grows yellow again in spring. It is also called snowy because the tongue is sticking out on a tree stump. The upper part of the tongue is the same color as the mud or the black part like the skin of persimmon. The lower part is the yellow carpet and the upper part is black or mud. The moon is yellow or pale yellow in color and has a mild taste and is light and easy to eat.
상황버섯이 기록된 옛문헌을 살펴보면, 동의보감에서는 '상목이'라 하여 탕액편에 소개되어 있고, 외형편에는 상황버섯을 쌀과 함께 넣어 죽을 끓여 복용하면 장풍, 하혈, 지루증상 등 각종 종양에 효과가 있다고 적고 있으며, 본초강목에는 차고 독성이 없으며, 온순하고 독을 다스리며, 여성의 하혈, 오장에 유리하고 양기에 좋다고 기록하고 있다. 또한, 고려 향약집성방에는 상황버섯이 부인병, 특히 염증에 효과가 크고 위, 대장, 직장, 식도 등 소화기 계통의 질환에 큰 효과가 있다고 기록하고 있으며, 동양의학대사전에는 독성이 없고 온화하고 독을 다스리고 오장에 좋고 위장에 이롭다 하여 복통에 썼으며, 난소 고환이 아프거나, 여성 대하, 산후지혈 등에 효과가 있는 것으로 기록하고 있다.Looking at the old literature where situation mushrooms were recorded, in Dongbobogam, 'Sangmok' is introduced in the liquid juice pieces, and on the outer side, it is effective on various tumors such as intestinal wind, bleeding, and seborrheic symptoms when boiled porridge with the situation mushrooms with rice. It is written that there is no cold and toxic in herbaceous wood, gentle and poisonous, women's bleeding, five intestines and good for yang good. In addition, the Korea Hyanggyeongbang Room records that situation mushrooms are particularly effective for gynecological diseases, especially inflammation, and have a great effect on diseases of the digestive system such as stomach, colon, rectum, and esophagus. It's good for the five intestines and it's good for the stomach, and it's used for abdominal pain.
또한, 중국 신농본초경에는 술독에 의한 주독에 신(神)과 같은 효험이 있다 하였으며, 실제 복용하면 위장질환 개선과 숙취 후 회복이 빠르고 심신이 지쳐있고 면역능력이 저하된 환자에게 작용하여 면역세포를 활성화 시킴으로써 건강회복에 큰 도움을 주는 것으로도 알려져 있다.In addition, the Chinese new agricultural herbal medicine has the same effect as the god to the poisoning caused by alcohol poisoning, and when taken in practice, it improves gastrointestinal diseases and recovers quickly after a hangover, and it works on patients who are exhausted and exhausted and have reduced immunity. It is also known to help the recovery of health by activating.
이러한 상황버섯은 칼륨, 칼슘, 마그네슘, 비타민 B2, B3, C, 섬유질 및 아미노산 등의 영양소가 함유되어 있으며, 인체 내 면역기능을 강화하는데 탁월한 베타글루칸이라는 다당체가 다량 함유되어 있다. 베타글루칸은 면역기능을 향상시켜 바이러스, 박테리아, 곰팡이 균, 기생충, 항암작용, 유리기 등에 효과가 있는 것으로 알려져 있다. 다당류에 대한 연구는 수천 건에 달하며 각종 질환, 대장균, 폐질환, 타박상사고, 해독작용, 알러지, 노화, 각종 바이러스 감염 등의 치료에 사용되어 왔으며, 현재까지 나온 면역 강화제 중에서 가장 우수한 것으로 알려져 있다. 우리 몸에 암세포가 끊임없이 생겨나지만 암세포에 대항하여 암에 걸리지 않게 되는 것은 면역세포들 때문으로 우리 몸에 있는 여러 가지 면역세포들의 작용을 활성화시켜 암세포를 공격하거나 분열을 억제시키는 항암작용을 하는 주요 성분이 베타글루칸이다. 그 베타글루칸이 상황버섯에 많이 함유되어 있다.These mushrooms contain nutrients such as potassium, calcium, magnesium, vitamins B2, B3, C, fiber and amino acids, and contain a large amount of beta-glucan, which is excellent for enhancing immune function in the human body. Beta-glucan is known to be effective in improving the immune function, viruses, bacteria, fungi, parasites, anticancer activity, free radicals. Thousands of studies on polysaccharides have been used in the treatment of various diseases, Escherichia coli, lung diseases, bruises, detoxification, allergies, aging, and various viral infections, and are known to be the best immune enhancers to date. The cancer cells constantly develop in our body, but the cancer cells are not caught by cancer because of the immune cells. It is the main ingredient that activates the action of various immune cells in our body to attack cancer cells or inhibit the division. This is beta glucan. The beta glucan is a lot of situation mushrooms.
상황버섯에 다량으로 함유되어 있는 베타글루칸은 면역세포와 같은 면역기능에 영향을 미치는 많은 세포들을 활성화시켜 우리 몸에서 암세포 등을 공격하거나 증식을 억제함으로 암을 이길 수 있는 힘을 제공하며, 이는 건강한 사람이라도 예방적 차원에서 베타글루칸의 섭취가 유익하다는 것을 말하는 것이다.Beta-glucan, which is contained in a large amount of situational mushrooms, activates many cells that affect immune functions such as immune cells, thereby providing the power to overcome cancer by attacking cancer cells or inhibiting proliferation in our bodies. Even humans are saying that beta-glucan is beneficial for preventive purposes.
따라서, 상황버섯으로부터 보다 많은 함량의 베타글루칸을 갖는 상황버섯 발효 추출물의 제조방법이 요원한 실정이다.Therefore, the situation of producing a situation mushroom fermentation extract having a higher content of beta glucan from the situation mushroom is a long situation.
따라서, 본 발명의 목적은 상기와 같은 종래의 문제점을 감안하여 안출한 것으로, 베타글루칸의 함량이 대폭 증가된 상황버섯 발효 추출물의 제조 방법 및 그 추출물을 제공하는 것이다.Accordingly, it is an object of the present invention to provide a method for producing a situation mushroom fermentation extract with a significant increase in the content of beta glucan, and the extract.
상기한 목적을 달성하기 위한 본 발명의 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법은, 상황버섯 배양 배지를 준비하는 단계; 상기 상황버섯 배양 배지에 종균(균사체)를 접종하여 액상의 배양물을 수득하는 단계; 상기 수득된 액상의 상황버섯 배양물을 발효하는 단계; 및 상기 발효된 상황버섯 배양물로부터 상황버섯 발효 추출물 추출하는 단계를 포함하여 이루어지는 것을 특징으로 한다.Method for producing a high content of beta glucan containing mushroom mushroom fermentation extract of the present invention for achieving the above object, preparing a mushroom culture medium; Inoculating the spawn (mycelium) in the situation mushroom culture medium to obtain a liquid culture; Fermenting the obtained liquid situation mushroom culture; And extracting a situation mushroom fermentation extract from the fermented situation mushroom culture.
여기서, 상기 배양(발효)의 조건은 온도 20~35℃, 상대습도 70~90%, 배양 기간 7~45일 수 있다.Here, the conditions of the culture (fermentation) may be a temperature 20 ~ 35 ℃, relative humidity 70 ~ 90%, culture period 7 ~ 45 days.
또한, 상기 추출에 사용되는 용매로는 물 또는 저급 에탄올일 수 있다.In addition, the solvent used for the extraction may be water or lower ethanol.
또한, 상기 제조방법에 따라 제조되는 고함량의 베타글루칸 함유 상황버섯 발효 추출물을 제공할 수 있다.In addition, it is possible to provide a high content of beta glucan-containing situation mushroom fermented extract prepared according to the production method.
여기서, 상기 베타글루칸 함량이 0.94mg/g 이상인 것이 바람직하다.Herein, the beta glucan content is preferably 0.94 mg / g or more.
상기와 같이 구성되는 본 발명의 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법에 의하면, 발효된 상황버섯 배양물로부터 상황버섯 발효 추출물을 추출함으로써, 고함량의 베타글루칸이 함유된 상황버섯 발효 추출물을 제조할 수 있는 효과가 있다.According to the manufacturing method of the high content beta glucan-containing situation mushroom fermentation extract of the present invention configured as described above, by extracting the situation mushroom fermentation extract from the fermented situation mushroom culture, the situation mushroom fermentation containing a high content of beta glucan There is an effect that can produce an extract.
도 1은 본 발명의 실시예 1로부터 수득한 상황버섯 발효 추출물로 성분 분석한 베타글루칸 성분 함량을 시험 검사한 성적서이다.Figure 1 is a test report of the content of beta glucan component analysis of the constituent mushroom fermentation extract obtained from Example 1 of the present invention.
이하, 본 발명을 첨부 도면을 참고하여 바람직한 실시형태에 의해 보다 자세하게 설명하지만, 본 발명이 이하의 실시형태에 한정되는 것이 아니며 그 요지의 범위 내에서 여러 가지로 변형하여 실시할 수 있음은 물론이다. 또한, 상세한 설명에서는 잘 알려진 구성 요소, 잘 알려진 동작 및 잘 알려진 기술들은 본 발명이 모호하게 해석되는 것을 피하기 위하여 구체적으로 설명되지 않는다.EMBODIMENT OF THE INVENTION Hereinafter, although this invention is demonstrated in detail by preferred embodiment with reference to an accompanying drawing, this invention is not limited to the following embodiment, Of course, it can be variously modified and implemented within the range of the summary. . In addition, well-known components, well-known operations and well-known techniques are not described in detail in the detailed description to avoid obscuring the present invention.
본 명세서에서 사용된 용어들은 실시형태를 설명하기 위한 것이며 본 발명을 제한하고자 하는 것은 결코 아니다. 본 명세서에서, 단수형은 문구에서 특별히 언급하지 않은 한 복수형도 포함한다. 또한, '포함(또는, 구비)한다'로 언급된 구성 요소 및 동작은 하나 이상의 다른 구성요소 및 동작의 존재 또는 추가를 배제하지 않는다.The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. In this specification, the singular also includes the plural unless specifically stated otherwise in the text. In addition, components and operations referred to as 'includes (or includes)' do not exclude the presence or addition of one or more other components and operations.
본 발명의 발명자들은 상황버섯의 다양한 약리 활성에 착안하여, 상황버섯 배양 배지에 균사체를 접종하여 발효시켜 상황버섯 발효 추출물을 추출함으로써, 베타글루칸 순도가 높은 상황버섯 추출물을 확인하여 본 발명을 완성하였다.The inventors of the present invention focus on various pharmacological activities of situation mushrooms, inoculate and ferment the mycelium to the situation mushroom culture medium to extract the situation mushroom fermentation extract, confirming the situation mushroom extract with high purity of beta glucan to complete the present invention. .
본 발명의 상황버섯은 목질진흙버섯으로 알려진 펠리누스 린테우스(Phellinus linteus)인 것이 바람직하다.The situation mushroom of the present invention is preferably Phellinus linteus known as woody mud mushrooms.
본 발명의 상황버섯 균사체는 상황버섯 종균을 종배양시켜 제조될 수 있다. 상기 상황버섯 종균은 사용시까지 주기적으로 계대 배양하여 유지할 수 있는데, 바람직한 구체예로서, PDA(Potato Dextrose Agar) 배지에 상황버섯 균사체를 접종한 후 약 25℃ 정도의 온도에서 약 4주 간격으로 계대 배양하여 유지할 수 있다.The situation mushroom mycelium of the present invention can be prepared by culturing the situation mushroom seed. The situation mushroom spawn can be maintained by subcultured periodically until use. As a preferred embodiment, the inoculation of the situation mushroom mycelium in PDA (Potato Dextrose Agar) medium is passaged at intervals of about 4 weeks at a temperature of about 25 ℃. Can be maintained.
상기 종배양은 보관 중인 상황버섯 균사체 종균을 본 배양에 앞서 배양하는 과정이다. 바람직한 구체예로서, 상기 종배양은 버섯 균사체용 배지에 종균, 즉 균사체를 접종한 후, 이를 회전 진탕 배양하여 액상의 배양물로서 수득할 수 있다.The seed culture is a process of incubating the mycelium mushroom mycelium spawn in storage prior to the present culture. In a preferred embodiment, the seed culture may be obtained as a liquid culture by inoculating the seed material, that is, the mycelium in the medium for mushroom mycelium, and then rotating shaking the culture.
한편, 상기 상항 버섯 배양물에 탱자 천연 발효물로부터 분리하여 동정한 바실러스(Bacillus) 균주를 추가 접종할 수도 있다.On the other hand, it can be further inoculated Bacillus (Bacillus) strain identified by separating from the natural fermentation of Tangza in the mushroom culture.
여기서, 상황버섯 균사체를 접종한 후, 배양(발효) 과정을 거치는데, 상기 배양의 조건은 온도 20~35℃, 상대습도 70~90%, 배양 기간 7~45일인 것이 바람직하며, 바람직한 구체예로서, 25℃의 온도에서 상대습도 80%의 배양기에서 30일 동안 배양(발효)시킬 수 있다.Here, after inoculating the situation mushroom mycelium, the culture (fermentation) process is carried out, the conditions of the culture is preferably 20 ~ 35 ℃, relative humidity 70 ~ 90%, 7 ~ 45 days incubation period, preferred embodiments As an example, it may be incubated (fermented) for 30 days in an incubator having a relative humidity of 80% at a temperature of 25 ° C.
발효가 완성된 상황버섯 발효 배양물은 상황버섯 균사체가 전체적으로 덮여 있는 형상이며, 이로부터 상황버섯 발효 추출물을 제조한다.The fermented culture of the situation mushroom fermentation is a shape that is covered with the mushroom mushroom mycelium as a whole, from which to prepare a mushroom extract fermentation.
추출에 사용되는 용매로는 물 또는 저급 에탄올일 수 있으나, 바람직하게는 열수 추출이다 바람직한 구체예로서, 수득된 상황버섯 배양물에 약 5~150배 부피의 열수를 가하고, 1~5시간 동안 진탕시키고, 원심분리하여 상등액을 취할 수 있다. 상기 과정은 1~5회 수행될 수 있으며, 바람직하게는 3회 반복 추출할 수 있다.The solvent used for the extraction may be water or lower ethanol, but preferably hot water extraction. In a preferred embodiment, about 5 to 150 times the volume of hot water is added to the obtained mushroom culture and shaken for 1 to 5 hours. Supernatant can be taken by centrifugation. The process may be performed 1 to 5 times, preferably three times repeated extraction.
위와 같은 공정을 거쳐 본 발명의 상황버섯 발효 추출물을 제조할 수 있다.Through the above process can be prepared a situation mushroom fermented extract of the present invention.
따라서, 본 발명은 본 발명의 상기 제조 방법으로 수득되는 상황버섯 발효 추출물을 제공한다.Therefore, the present invention provides a situation mushroom fermented extract obtained by the above production method of the present invention.
본 발명의 제조 방법에 따라 제조되는 상기 상황버섯 발효 추출물은 상황버섯 발효에 의하여 상황버섯 균사체에 다량으로 존재하는 다양한 약리 효과를 나타내는 성분들이 존재하고, 베타클루칸의 함량을 대폭 증가시킬 수 있게 되는 것이다.The situation mushroom fermented extract prepared according to the production method of the present invention is a component that exhibits various pharmacological effects present in the situation mushroom mycelium in a large amount by the situation mushroom fermentation, it is possible to significantly increase the content of beta glucan will be.
상기 상황버섯 발효 추출물은 사용 목적에 적합하게 액상, 분말상 등으로 제조될 수 있으며, 특히 분말상의 경우에는 상황버섯 발효 추출물을 감압 농축하여 분말화시킬 수 있다.The situation mushroom fermentation extract may be prepared in a liquid, powder, etc. to suit the purpose of use, in particular, in the case of powder may be concentrated by vacuum concentration of the situation mushroom fermentation extract.
본 발명의 상황버섯 발효 추출물은 고함량의 베타글루칸이 함유되어 있어 인간의 정상적인 세포조직의 면역기능을 활성화시켜 암세포의 증식과 재발을 억제하고 면역세포의 기능을 활발하게 하는 인터루킨(interleukin), 인터페론(interferon)의 생성을 촉진시키며, 암세포가 있는 체내로 들어가 사이토카인(Cytokine)을 생산시킴으로써, 면역 세포인 T 세포와 B 세포의 활동을 지원하여 세포조직의 면역기능을 활성화 시켜준다.Situation mushroom fermented extract of the present invention contains a high content of beta glucan to activate the immune function of human normal cellular tissues to inhibit the proliferation and recurrence of cancer cells, interleukin (interleukin), interferon to activate the function of immune cells It promotes the production of interferons and enters the body with cancer cells to produce cytokines, thereby supporting the activity of immune cells, T cells and B cells, thereby activating the immune function of cellular tissues.
또한, 이러한 고함량의 베타글루칸이 함유된 상황버섯 발효추출물에 의해 예를 들어, 대장암, 유방암, 전립선암, 간암, 췌장암 또는 위암 등의 각종 악성 종양, 세균성 질환, 진균질환, 고혈압, 우울증, 경련, 바이러스성 질환, 통증, 위장 장애, 심장 기능 저하, 흉통, 감기, 당뇨, 설사, 이질, 부종, 신경통, 신경쇠약, 류마티스성 관절염, 노화, 각종 염증 질환, 불면증, 천식 등의 예방 또는 치료용의 약학적 조성물로 사용될 수 있을 것이다.In addition, the situation mushroom fermented extract containing high content of beta-glucan, for example, various malignant tumors, such as colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer or stomach cancer, bacterial diseases, fungal diseases, high blood pressure, depression, Prevention or treatment of convulsions, viral diseases, pain, gastrointestinal disorders, heart failure, chest pain, colds, diabetes, diarrhea, dysentery, edema, neuralgia, nervous breakdown, rheumatoid arthritis, aging, various inflammatory diseases, insomnia, asthma It may be used as a pharmaceutical composition for a dragon.
본 발명의 약학적 조성물은 각각의 사용 목적에 맞게 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁제, 에멀젼, 시럽, 에어로졸 등의 경구 제형, 멸균 주사용액의 주사제 또는 크림, 로션 등의 피부 외용제 등의 다양한 형태로 제형화하여 사용할 수 있으며, 경구 투여하거나 정맥 내, 복강 내, 피하, 직장, 국소 투여 또는 피부에 도포하는 등을 포함한 다양한 경로를 통해 투여될 수 있다 이러한 약학적 조성물에는 추가적으로 담체, 부형제 또는 희석제 등이 더 포함될 수 있으며, 포함될 수 있는 적합한 담체, 부형제 또는 희석제의 예로는 락토오스, 덱스트로오스, 수크로오스, 솔비톨, 만니톨, 자일리톨, 에리쓰리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로스, 메틸 셀룰로스, 비정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유 등을 들 수 있다 또한, 본 발명의 약학적 조성물은 충전제, 항응집제, 윤활제, 습윤제, 향료, 유화제, 방부제 등을 추가로 더 포함할 수도 있다.The pharmaceutical composition of the present invention may be orally formulated as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, injections or creams, lotions, etc. It may be formulated and used in various forms, such as an external preparation for skin, and may be administered orally or through various routes including intravenous, intraperitoneal, subcutaneous, rectal, topical administration, or application to the skin. Additional carriers, excipients or diluents may further be included, and examples of suitable carriers, excipients or diluents that may be included include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber , Alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, amorphous cellulose, Polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, mineral oil and the like. In addition, the pharmaceutical composition of the present invention may be a filler, an anticoagulant, a lubricant, a humectant, The fragrance, emulsifier, and preservative may further be included.
본 발명의 약학적 조성물은 약제학적으로 유효한 양으로 투여한다 본 발명에서, "약제학적으로 유효한 양"은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효 용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다 본 발명의 약학적 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고, 종래의 치료제와 순차적으로 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다 상기한 요소들을 모두 고려하여 부작용 없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and effective Dosage levels will be determined by the type of disease, severity, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of drugs, and other factors well known in the medical field. The pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents, may be administered sequentially or simultaneously with conventional therapeutic agents, and may be administered as single or multiple doses. Therefore, it is important to administer the amount to obtain the maximum effect with the minimum amount without side effects, which is On can be readily determined by
바람직한 구체예로서, 본 발명의 약학적 조성물의 유효성분의 유효량은 환자의 나이, 성별, 체중에 따라 달라질 수 있으며, 일반적으로는 체중 당 1 내지 5,000mg, 바람직하게는 100 내지 3,000mg을 매일 또는 격일 투여하거나 1일 1 내지 3회로 나누어 투여할 수 있다. 그러나, 투여 경로, 질병의 중증도, 성별, 체중, 연령 등에 따라서 증감될 수 있으므로 상기 투여량이 어떠한 방법으로도 본 발명의 범위를 한정하는 것은 아니다.In a preferred embodiment, the effective amount of the active ingredient of the pharmaceutical composition of the present invention may vary depending on the age, sex, and weight of the patient, and generally 1 to 5,000 mg, preferably 100 to 3,000 mg per body weight daily or It can be administered every other day or divided into 1 to 3 times a day. However, the dosage may be increased or decreased depending on the route of administration, the severity of the disease, sex, weight, age, etc., and the above dosage does not limit the scope of the present invention in any way.
본 발명의 약학적 조성물은 다양한 경로를 통하여 대상에 투여될 수 있다 투여의 모든 방식은 예상될 수 있는데, 예를 들면, 피부, 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관 내(intracerebroventricular) 주사에 의해 투여될 수 있다. 본 발명에서 "투여"는 임의의 적절한 방법으로 환자에게 소정의 물질을 제공하는 것을 의미하며, 본 발명의 약학적 조성물의 투여 경로는 목적 조직에 도달할 수 있는 한 일반적인 모든 경로를 통하여 도포, 경구 또는 비경구 투여될 수 있다.The pharmaceutical compositions of the present invention can be administered to a subject through a variety of routes All modes of administration can be expected, for example, in the skin, oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular It can be administered by intracerebroventricular injection. As used herein, "administration" means providing a patient with any substance by any suitable method, wherein the route of administration of the pharmaceutical composition of the present invention is applied, orally, through all common routes as long as the target tissue can be reached. Or parenterally.
또한, 본 발명의 조성물은 유효성분을 표적 세포로 전달할 수 있는 임의의 장치를 이용해 투여될 수도 있다 본 발명에서 "대상"은, 특별히 한정되는 것은 아니지만, 예를 들어, 인간, 원숭이, 소, 말, 양, 돼지, 닭, 칠면조, 메추라기, 고양이, 개, 마우스, 쥐, 토끼 또는 기니아 피그를 포함하고, 바람직하게는 포유류, 보다 바람직하게는 인간을 의미한다.In addition, the composition of the present invention may be administered using any device capable of delivering the active ingredient to a target cell. In the present invention, the "subject" is not particularly limited, but for example, human, monkey, cow, horse , Sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, mice, rabbits or guinea pigs, preferably mammals, more preferably humans.
또한, 본 발명의 상황버섯 발효 추출물은 상기 설명된 다양한 생리 활성 성분이 다량으로 함유되어 있으므로, 예를 들어, 대장암, 유방암, 전립선암, 간암, 췌장암 또는 위암 등의 각종 악성 종양, 세균성 질환, 진균 질환, 고혈압, 우울증, 경련, 바이러스성 질환, 통증, 위장 장애, 심장 기능 저하, 흉통, 감기, 당뇨, 설사, 이질, 부종, 신경통, 신경쇄약, 류마티스성 관절염, 노화, 각종 염증 질환, 불면증, 천식 등의 예방 또는 개선용 건강 기능 식품으로 사용될 수 있을 것이다.In addition, the situation mushroom fermented extract of the present invention contains a large amount of the various physiologically active ingredients described above, for example, various malignant tumors, bacterial diseases, such as colon cancer, breast cancer, prostate cancer, liver cancer, pancreatic cancer or stomach cancer, Fungal diseases, high blood pressure, depression, convulsions, viral diseases, pain, gastrointestinal disorders, heart failure, chest pain, colds, diabetes, diarrhea, dysentery, swelling, neuralgia, nervous breakdown, rheumatoid arthritis, aging, various inflammatory diseases, insomnia It may be used as a dietary supplement for the prevention or improvement of asthma, etc.
본 발명의 건강 기능 식품은 상기 질환들의 예방 또는 개선에 효과적인 식품 및 음료 등에 다양하게 이용될 수 있다. 본 발명의 유효 성분을 포함하는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강보조 식품류 등이 있고, 분말, 과립, 정제, 캡슐 또는 음료인 형태로 사용할 수 있다. 본 발명의 유효성분은 일반적으로 전체 식품 중량의 001 내지 15중량%로 가할 수 있으며, 건강음료 조성물은 100ml를 기준으로 002 내지 10g, 바람직하게는 03 내지 1g의 비율로 가할 수 있다.The health functional food of the present invention can be used in various ways such as foods and beverages effective for the prevention or improvement of the above diseases. Examples of the food containing the active ingredient of the present invention include various foods, beverages, gums, teas, vitamin complexes, health supplements, and the like, and can be used in the form of powders, granules, tablets, capsules, or beverages. . The active ingredient of the present invention may generally be added in an amount of 001 to 15% by weight of the total food weight, and the health beverage composition may be added in a ratio of 002 to 10g, preferably 03 to 1g based on 100ml.
본 발명의 건강 기능 식품은 지시된 비율로 필수 성분으로서 상기 유효성분을 함유하는 것 외에 식품학적으로 허용 가능한 식품보조 첨가제, 예컨대, 천연 탄수화물 및 다양한 향미제 등을 추가 성분으로서 함유할 수 있다.The health functional food of the present invention may contain, in addition to the above-mentioned active ingredient as an essential ingredient in the indicated ratio, food supplements such as food supplements, such as natural carbohydrates and various flavoring agents, as additional ingredients.
상기 천연 탄수화물의 예로는 포도당, 과당 등의 단당류, 말토오스, 수크로오스 등의 이당류 및 덱스트린, 시클로덱스트린 등의 다당류와 같은 통상적인 당 및 자일리톨, 소르비톨, 에리쓰리톨 등의 당알코올이 있다.Examples of the natural carbohydrates include conventional sugars such as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
상기 향미제로는 타우마틴, 레바우디오시드 A, 글리시르히진, 사카린, 아스파르탐 등을 사용할 수 있다 상기 향미제의 비율은 본 발명의 건강 기능 식품 100ml당 일반적으로 약 1 내지 20g, 바람직하게는 약 5 내지 12g을 사용한다.As the flavoring agent, taumartin, rebaudioside A, glycyrrhizin, saccharin, aspartame, etc. may be used. The ratio of the flavoring agent is generally about 1 to 20 g per 100 ml of the health functional food of the present invention, preferably Uses about 5-12 g.
상기 외에 본 발명의 건강 기능 식품은 여러 가지 영양제, 비타민, 광물, 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 건강 기능 식품은 천연 과일 주스 및 과일 주스 음료 및 야채 음료 등의 제조를 위한 과육을 함유할 수도 있다.In addition to the above, the health functional food of the present invention includes various nutrients, vitamins, minerals, synthetic flavors and natural flavoring agents, colorants and neutralizing agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloids Thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks and the like. In addition, the health functional food of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage, vegetable beverage and the like.
이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 본 발명의 상기 유효성분 100중량부 당 001 내지 약 20중량부의 범위에서 선택되는 것이 일반적이다.These components can be used independently or in combination. The proportion of such additives is generally selected from the range of 001 to about 20 parts by weight per 100 parts by weight of the active ingredient of the present invention.
이하에서는 구체적인 실시예를 통하여 본 발명을 더욱 상세하게 설명한다 하기 실시예는 본 발명의 바람직한일 구체예를 나타낸 것이며, 하기 실시예에 의하여 본 발명의 권리범위가 하기 실시예의 범위로 한정되는 것이 아님은 자명하다.Hereinafter, the present invention will be described in more detail with reference to specific examples. The following examples illustrate preferred embodiments of the present invention, and the scope of the present invention is not limited to the following examples by the following examples. Is self explanatory.
[실시예]EXAMPLE
실시예Example 1 상황버섯 발효 추출물의 제조 1 Preparation of Situation Mushroom Fermented Extract
상황버섯(Phellinus linteus)은 (주)팜바이오스에서 계대중인 균주를 사용하여 25℃에서 PDA(Potato Dextrose Agar, Difco, Co, USA) 배지를 사용하여 배양하여, 4주 간격으로 계대배양하면서, 4℃에 보관하면서 사용하였다. 500ml 플라스크에 100ml 용량의 버섯 균사체 고체 배지(1 cm × 1 cm, 3개)에 계대 중인 상황버섯 균사체를 접종한 후, 회전 진탕 배양기(Daihan Labtech CoKorea, 25±1℃, 130rpm)에서 7일간 배양하여 액체 종균으로 사용하였다.Phellinus linteus was cultured using PDA (Potato Dextrose Agar, Difco, Co, USA) medium at 25 ° C. using strains passaged from Palmbio Co., Ltd. Used while storing at ℃. A 500 ml flask was inoculated with 100 g of mushroom mycelium solid medium (1 cm × 1 cm, 3 pieces) of subcultured mushroom mycelium, followed by incubation for 7 days in a rotating shake incubator (Daihan Labtech CoKorea, 25 ± 1 ° C, 130 rpm). It was used as a liquid spawn.
발효는 25℃, 상대습도 80%의 배양기에서 30일간 진행하였다. 발효 후 10배 부피의 열수를 첨가하여 2시간 동안 진탕 시킨 후, 72시간 침지하고, 10,000rpm으로 10분간 원심분리 후 상등액을 취하였으며, 이를 3회 반복 후 추출액을 감압 하에서 농축하여 분말로 조제하여 사용하였다.Fermentation was carried out for 30 days in an incubator at 25 ℃, relative humidity 80%. After fermentation, 10-fold volume of hot water was added, shaken for 2 hours, immersed for 72 hours, centrifuged at 10,000 rpm for 10 minutes, and then the supernatant was taken. After repeated three times, the extract was concentrated under reduced pressure to prepare a powder. Used.
실시예Example 2 상황버섯 발효 추출물의 베타글루칸 성분 분석 Analysis of Beta-glucans from Fermented Extracts of Situary Mushrooms
상기 실시예 1로부터 수득한 상황버섯 발효 추출물로 성분 분석한 베타글루칸 성분 함량을 시험 검사한 성적서로서 도 1에 나타난 바와 같다.As shown in Figure 1 as a test test result of the content analysis of the beta glucan component of the situation mushroom fermented extract obtained in Example 1.
도 1에 도시된 바와 같이, 0.94mg/g로 매우 높은 함량을 갖는 것으로 확인되었다.As shown in FIG. 1, it was found to have a very high content of 0.94 mg / g.
상기 본 발명의 상세한 설명에서는 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법에 대한 바람직한 실시형태에 대해 기술하였지만, 그 내용은 상기 실시형태에 기술된 내용에만 한정되지 않고, 이하의 특허청구범위에서 청구하는 본 발명의 요지를 벗어남이 없이 당해 발명이 속하는 분야에서 통상의 지식을 가진 자라면 누구든지 다양한 변경 실시가 가능한 범위까지 본 발명의 기술적 정신이 있다고 할 것이다.In the above detailed description of the present invention, a preferred embodiment of the method for preparing a high content of beta glucan-containing situation mushroom fermentation extract has been described, but the contents are not limited to the contents described in the above embodiments, and the following claims Without departing from the gist of the present invention claimed in the present invention, anyone of ordinary skill in the art will have the technical spirit of the present invention to the extent that various modifications can be made.
Claims (5)
상기 상황버섯 배양 배지에 종균(균사체)를 접종하여 액상의 배양물을 수득하는 단계;
상기 수득된 액상의 상황버섯 배양물을 발효하는 단계; 및
상기 발효된 상황버섯 배양물로부터 상황버섯 발효 추출물 추출하는 단계를 포함하여 이루어지는 것을 특징으로 하는 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법.
Preparing a situation mushroom culture medium;
Inoculating the spawn (mycelium) in the situation mushroom culture medium to obtain a liquid culture;
Fermenting the obtained liquid situation mushroom culture; And
Method for producing a high content beta glucan-containing situation mushroom fermentation extract comprising the step of extracting the situation mushroom fermentation extract from the fermented situation mushroom culture.
상기 상항 버섯 배양물에 탱자 천연 발효물로부터 분리하여 동정한 바실러스 (Bacillus)를 접종하는 단계를 더 포함하여 이루어지는 것을 특징으로 하는 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법.
The method of claim 1,
Method for producing a high content of beta glucan-containing situation mushroom fermentation extract, characterized in that it further comprises the step of inoculating Bacillus identified by separating the natural mushroom culture from the Tangerine fermentation (Bacillus).
상기 추출에 사용되는 용매로는 물 또는 저급 에탄올인 것을 특징으로 하는 고함량의 베타글루칸 함유 상황버섯 발효 추출물의 제조 방법.
The method of claim 1,
The solvent used for the extraction is a method for producing a high content beta glucan-containing situation mushroom fermentation extract, characterized in that water or lower ethanol.
A high content of beta glucan-containing situation mushroom fermented extract prepared according to any one of claims 1 to 3.
상기 베타글루칸 함량이 0.94mg/g 이상인 것을 특징으로 하는 고함량의 베타글루칸 함유 상황버섯 발효 추출물.
The method of claim 4, wherein
Beta-glucan-containing situation mushroom fermentation extract of high content, characterized in that the beta glucan content is more than 0.94mg / g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180037046A KR20190114400A (en) | 2018-03-30 | 2018-03-30 | Method for producing fermentation products of sanghwang mushroom |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020180037046A KR20190114400A (en) | 2018-03-30 | 2018-03-30 | Method for producing fermentation products of sanghwang mushroom |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190114400A true KR20190114400A (en) | 2019-10-10 |
Family
ID=68206137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020180037046A KR20190114400A (en) | 2018-03-30 | 2018-03-30 | Method for producing fermentation products of sanghwang mushroom |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20190114400A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115011485A (en) * | 2021-03-05 | 2022-09-06 | 葡萄王生技股份有限公司 | Phellinus linteus mycelium and/or its derivative, its preparation method and its use for preparing sleep improving composition |
| KR20240030496A (en) | 2022-08-31 | 2024-03-07 | (주)네오크레마 | A Culture Composition For Culturing Sanghwang Mushroom Mycelial And A Method Of Culturing The Same |
-
2018
- 2018-03-30 KR KR1020180037046A patent/KR20190114400A/en unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115011485A (en) * | 2021-03-05 | 2022-09-06 | 葡萄王生技股份有限公司 | Phellinus linteus mycelium and/or its derivative, its preparation method and its use for preparing sleep improving composition |
| CN115011485B (en) * | 2021-03-05 | 2024-05-31 | 葡萄王生技股份有限公司 | Phellinus linteus mycelium, method for producing extract concentrate thereof, and use thereof for producing sleep improving composition |
| KR20240030496A (en) | 2022-08-31 | 2024-03-07 | (주)네오크레마 | A Culture Composition For Culturing Sanghwang Mushroom Mycelial And A Method Of Culturing The Same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102894207B (en) | Body-immunity-enhancing composite Chinese herbal medicine pig feed additive and preparation method thereof | |
| CN103141702B (en) | Chinese herb extract feed additive capable of effectively preventing and treating porcine epizootic diarrhea | |
| JP6998613B2 (en) | A method for producing a composition for preventing, improving or treating the deterioration of intestinal function containing a bamboo shoot enzyme decomposition product or a bamboo shoot fermented product as an active ingredient. | |
| KR101718323B1 (en) | Pharmaceutical composition containing fermented Rhus verniciflua extracts for prevention or treatment of gastritis, gastric ulcer, duodenal ulcer, gastric cancer and gastric mucosal injury | |
| CN103877122A (en) | Production method and donkey-hide gelatin of Chinese herbal donkey-hide gelatin material | |
| KR20190114400A (en) | Method for producing fermentation products of sanghwang mushroom | |
| TWI791941B (en) | Use of a composition containing an extract of mushroom and/ or culture substrate thereof for treating drpression and emotional regulation | |
| KR102254420B1 (en) | Antimicrobial composition comprising the fermentation extract of medicinal or edible natural products | |
| CN109430854B (en) | Health product and preparation method thereof | |
| KR101033671B1 (en) | Anticancer health foods including Phellinus linteus and vegetable worms | |
| KR101851395B1 (en) | Extract of graviola fermented by phellinus linteus and manufacturing method thereof | |
| CN109527583A (en) | The new application of Morchella esculenta (L.) Pers sporophore polypeptide | |
| CN102342961B (en) | Application of morchella esculenta in composition used for preventing and treating stomach ulcer | |
| CN104799289A (en) | Compound nutritious food with antineoplastic and immunity enhancement functions and production method for compound nutritious food antineoplastic and immunity enhancement functions | |
| CN104906140A (en) | Donkey-hide gelatin, a preparation method and associated equipment | |
| KR101618503B1 (en) | Novel endolichenic fungi and composition for preventing or treatment of gastric cancer or colorectal cancer comprising extracts thereof | |
| KR101862836B1 (en) | Pharmaceutical composition comprising heracleum moellendorffii hance extract for preventing or treating depression | |
| CN112043730A (en) | Traditional Chinese medicine biological preparation for preventing and treating animal epidemic diseases | |
| KR101062003B1 (en) | Composition for the prevention and the treament of diabetes containing Alnus firma Sieb. et Zucc extracts or compounds separated therefrom as an effective ingredient | |
| KR20120132646A (en) | Liquid cultivating method of Phellinus linteus increasing antioxidant and immunostimulating activity | |
| KR102231383B1 (en) | A pharmaceutical composition for the treatment of metabolic diseases comprising the fermentative products of Kalopanax septemlobus as an active ingredient | |
| KR20050074395A (en) | The method for producing a high-funtional bio feed and product thereof | |
| KR20110118748A (en) | Compositions for prevention and improvement of cancer containing the extracts of ligularia fischeri var. spiciformis nakai as an active ingredient | |
| KR102239159B1 (en) | Pharmaceutical composition comprising the extract of medicinal or edible natural products as an effective component for prevention or treatment of diabetes and health functional food comprising the same | |
| JP2002187851A (en) | Prophylactic and remedial medicine for diabetes and functional foods including the same |